German S1 guideline: Contact dermatitis.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
26
12
2021
accepted:
05
01
2022
pubmed:
9
5
2022
medline:
20
5
2022
entrez:
8
5
2022
Statut:
ppublish
Résumé
Contact dermatitis is an inflammation of the epidermis and dermis at the site of exposure triggered by external agents. The two main forms are irritant and allergic contact dermatitis, which cause significant health and socioeconomic costs in addition to a marked reduction in quality of life. The anamnesis and the clinical picture are decisive for the necessary diagnostic measures. The most accurate possible diagnostic classification of contact dermatitis by means of allergological testing is important for disease management, since not only classical eczema therapy but also avoidance of the exogenous triggering factors are of great importance here. The choice of therapy should be based on the acuity, clinical severity, morphology of the lesions and localization of the contact dermatitis. A combination of basic therapy, topical, physical, and systemic therapy adapted to the patient's needs is required, whereby not all forms of therapy must be carried out simultaneously but can be used in a varying manner. Primary, secondary, and tertiary prevention strategies aim at the recognition of the triggering noxae or allergens with subsequent contact avoidance or minimization. The present S1-guideline on contact dermatitis is primarily intended to provide dermatologists, allergologists and physicians working in allergology and occupational dermatology with a decision-making aid for the selection and implementation of suitable and sufficient diagnostics, therapy, and prevention.
Substances chimiques
Allergens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
712-734Informations de copyright
© 2022 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Brasch J, Becker D, Aberer W et al. Guideline contact dermatitis. S1-Guideline of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG. Allergo J Int 2014; 23: 126-38.
Diepgen TL, Andersen KE, Chosidow O et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges 2015; 13: e1-e22.
Diepgen TL, Andersen KE, Chosidow O et al. Guidelines for diagnosis, prevention and treatment of hand eczema - short version. J Dtsch Dermatol Ges 2015; 13: 77-85.
Diepgen TL, Elsner P, Schliemann S et al. Management von Handekzemen - Leitlinie - LCD-10-Ziffer: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges 2009; 7 (Suppl. 3): S1-S16.
Weyandt G, Breitkopf C, Werner RN et al. German S1 guidelines for the diagnosis and treatment of perianal dermatitis (anal eczema). J Dtsch Dermatol Ges 2020; 18: 648-57.
Martin SF, Bonefeld CM. Mechanisms of irritant and allergic contact dermatitis. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 95-120.
Gonçalo M. Phototoxic and photoallergic contact reactions. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 365-89.
Goossens A, Amaro C, Mahler V. Protein contact dermatitis. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 355-64.
Cashman MW, Reutemann PA, Ehrlich A. Contact dermatitis in the United States: epidemiology, economic impact, and workplace prevention. Dermatol Clin 2012; 30: 87-98, viii.
Coenraads PJ, Gonçalo M. Skin diseases with high public health impact. Contact dermatitis. Eur J Dermatol 2007; 17: 564-5.
Bains SN, Nash P, Fonacier L. Irritant contact dermatitis. Clin Rev Allergy Immunol 2019; 56: 99-109.
Diepgen TL, Ofenloch RF, Bruze M et al. Prevalence of contact allergy in the general population in different European regions. Br J Dermatol 2016; 174: 319-29.
Thyssen JP, Johansen JD, Linneberg A, Menné T. The epidemiology of hand eczema in the general population - prevalence and main findings. Contact Dermatitis 2010; 62: 75-87.
Hermann-Kunz E. Allergische Krankheiten in Deutschland. Ergebnisse einer repräsentativen Studie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2000; 43: 400-6.
Admani S, Jacob SE. Allergic contact dermatitis in children: review of the past decade. Curr Allergy Asthma Rep 2014; 14: 421.
Alinaghi F, Bennike NH, Egeberg A et al. Prevalence of contact allergy in the general population: A systematic review and meta-analysis. Contact Dermatitis 2019; 80: 77-85.
Prakash AV, Davis MD. Contact dermatitis in older adults: a review of the literature. Am J Clin Dermatol 2010; 11: 373-81.
Simonsen AB, Deleuran M, Johansen JD, Sommerlund M. Contact allergy and allergic contact dermatitis in children - a review of current data. Contact Dermatitis 2011; 65: 254-65.
Ward DB, Fleischer AB, Jr, Feldman SR, Krowchuk DP. Characterization of diaper dermatitis in the United States. Arch Pediatr Adolesc Med 2000; 154: 943-6.
Schnuch A, Uter W, Geier J, Gefeller O. Epidemiology of contact allergy: an estimation of morbidity employing the clinical epidemiology and drug-utilization research (CE-DUR) approach. Contact Dermatitis 2002; 47: 32-9.
Schmitz R, Thamm M, Ellert U et al. Verbreitung häufiger Allergien bei Kindern und Jugendlichen in Deutschland: Ergebnisse der KiGGS-Studie - Erste Folgebefragung (KiGGS Welle 1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014; 57: 771-8.
Lantinga H, Nater JP, Coenraads PJ. Prevalence, incidence and course of eczema on the hands and forearms in a sample of the general population. Contact Dermatitis 1984; 10: 135-9.
Mahler V. Umweltassoziierte dermatologische Erkrankungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 605-17.
Esser PR, Martin SF. Erweitertes Verständnis von Pathogenese und Therapie der Kontaktallergie. Hautarzt 2020; 71: 174-81.
Karlberg AT, Börje A, Duus Johansen J et al. Activation of non-sensitizing or low-sensitizing fragrance substances into potent sensitizers - prehaptens and prohaptens. Contact Dermatitis 2013; 69: 323-34.
Ott H, Bergström MA, Heise R et al. Cutaneous metabolic activation of carvoxime, a self-activating, skin-sensitizing prohapten. Chem Res Toxicol 2009; 22: 399-405.
Sharma A, Saito Y, Hung SI et al. The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. J Immunotoxicol 2019; 16: 1-12.
Schmidt M, Raghavan B, Müller V et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010; 11: 814-9.
Adam C, Wohlfarth J, Haussmann M et al. Allergy-inducing chromium compounds trigger potent innate immune stimulation via ROS-dependent inflammasome activation. J Invest Dermatol 2017; 137: 367-76.
Sieben S, Kawakubo Y, Masaoudi TA et al. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol 2002; 109: 1005-11.
Kohli N, Nedorost S. Inflamed skin predisposes to sensitization to less potent allergens. J Am Acad Dermatol 2016; 75: 312-7.e1.
Blömeke B, Brans R, Dickel H et al. Association between TNFA-308 G/A polymorphism and sensitization to para-phenylenediamine: a case-control study. Allergy 2009; 64: 279-83.
Friedmann PS, Sanchez-Elsner T, Schnuch A. Genetic factors in susceptibility to contact sensitivity. Contact Dermatitis 2015; 72: 263-74.
Blömeke B, Brans R, Coenraads PJ et al. Para-phenylenediamine and allergic sensitization: risk modification by N-acetyltransferase 1 and 2 genotypes. Br J Dermatol 2009; 161: 1130-5.
Werfel T, Allam JP, Biedermann T et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336-49.
Molin S, Vollmer S, Weiss EH et al. Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. Br J Dermatol 2009; 161: 801-7.
Thyssen JP, Linneberg A, Ross-Hansen K et al. Filaggrin mutations are strongly associated with contact sensitization in individuals with dermatitis. Contact Dermatitis 2013; 68: 273-6.
Scheinman PL, Vocanson M, Thyssen JP et al. Contact dermatitis. Nat Rev Dis Primers 2021; 7: 38.
Litchman G, Nair PA, Atwater AR, Bhutta BS. Contact dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021:
Bonamonte D, Foti C, Vestita M, Angelini G. Noneczematous contact dermatitis. ISRN Allergy 2013; 2013: 361746.
Geier J, Struppek K. Anamnese-Auxilium für die berufsdermatologische Untersuchung von Maurern, Betonbauern, Fliesenlegern und Angehörigen verwandter Berufe. Derm Beruf Umwelt 1995; 43: 75-80.
Geier J, Brehler R, Eck E et al. Berufsspezifische Epikutantestung bei Maurern und Angehörigen verwandter Berufe. Empfehlungen der Arbeitsgruppe „Berufs-Testreihen“ der Deutschen Kontaktallergie-Gruppe. Derm Beruf Umwelt 1999; 47: 29-33.
Hillen U, Brehler R, Dickel H et al. Berufsspezifische Epikutantestung bei Malern und Lackierern - Empfehlungen der Arbeitsgruppe „Berufs-Testreihen“ der Deutschen Kontaktallergie-Gruppe. Dermatol Beruf Umwelt 2006; 54: 47-52.
Koch P, Brehler R, Eck E et al. Berufsspezifische Epikutantestung für Angehörige der Heil- und Pflegeberufe. Dermatol Beruf Umwelt 2002; 50: 155-62.
Proske S, Brehler R, Dickel H et al. Berufsspezifische Epikutantestung in der Altenpflege: Empfehlungen der Arbeitsgruppe "Berufs-Testreihen" der Deutschen Kontaktallergie-Gruppe. Dermatol Beruf Umwelt 2005; 53: 50-3.
Uter W, Wulfhorst B, Pilz B, Raguz J. Anamnese-Auxilium für das Friseurgewerbe - Dermatologiosches Risikoprofil. Derm Beruf Umwelt 1997; 45: 165-9.
Uter W. Epidemiologie und Prävention von Handekzemen in Feuchtberufen am Beispiel des Friseurhandwerks., 1st Auflage, Universitätsverlag Rasch, Osnabrück, 1999.
Wessbecher R, Straube M, Szliska C, Schwanitz HJ. Anamneseauxilium und gewerbedermatologische Beurteilung bei medizinischen Bademeistern, Masseuren und Physiotherapeuten. Hautarzt 1998; 49: 912-9.
Geier J, Bauer A, Becker D et al. Empfehlungen der Arbeitsgruppe „Photopatchtest“ der Deutschen Kontaktallergie-Gruppe (DKG) zur Durchführung des Photopatchtests. J Dtsch Dermatol Ges 2018; 16: 1363-4.
Gonçalo M. Photopatch testing. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 593-608.
Lehmann P. Diagnostic approach to photodermatoses. J Dtsch Dermatol Ges 2006; 4: 965-75.
Mahler V. Hand dermatitis - differential diagnoses, diagnostics, and treatment options. J Dtsch Dermatol Ges 2016; 14: 7-26.
Mahler V, Nast A, Bauer A et al. S3 guidelines: Epicutaneous patch testing with contact allergens and drugs - Short version, Part 1. J Dtsch Dermatol Ges 2019; 17: 1076-93.
Mahler V, Nast A, Bauer A et al. S3 guidelines: Epicutaneous patch testing with contact allergens and drugs - Short version, Part 2. J Dtsch Dermatol Ges 2019; 17: 1187-207.
Pesonen M, Koskela K, Aalto-Korte K. Contact urticaria and protein contact dermatitis in the Finnish Register of Occupational Diseases in a period of 12 years. Contact Dermatitis 2020; 83: 1-7.
Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 1): 4-12.
Nosbaum A, Vocanson M, Rozieres A et al. Allergic and irritant contact dermatitis. Eur J Dermatol 2009; 19: 325-32.
Mahler V, Dickel H. Wichtigste Kontaktallergene beim Handekzem. Hautarzt 2019; 70: 778-89.
Aalto-Korte K, Suuronen K, Frosch PJ. Patch testing with the patients’ own products. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 551-69.
Brockow K, Przybilla B, Aberer W et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int 2015; 24: 94-105.
Darsow U, Balzer C, Mahler V, Ring J. Atopy patch testing with aeroallergens and food proteins. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 619-30.
Dickel H, Geier J, Kreft B et al. Comparing reliabilities of strip and conventional patch testing. Contact Dermatitis 2017; 76: 342-9.
Dickel H, Kuhlmann L, Bauer A et al. Atopy patch testing with aeroallergens in a large clinical population of dermatitis patients in Germany and Switzerland, 2000-2015: a retrospective multicentre study. J Eur Acad Dermatol Venereol 2020; 34: 2086-95.
Fischer LA, Voelund A, Andersen KE et al. The dose-response relationship between the patch test and ROAT and the potential use for regulatory purposes. Contact Dermatitis 2009; 61: 201-8.
Johansen JD, Bruze M, Andersen KE et al. The repeated open application test: suggestions for a scale of evaluation. Contact Dermatitis 1998; 39: 95-6.
Niinimaki A. Scratch-chamber tests in food handler dermatitis. Contact Dermatitis 1987; 16: 11-20.
Slodownik D, Lee A, Nixon R. Irritant contact dermatitis: a review. Australas J Dermatol 2008; 49: 1-9; quiz 10-1.
John SM, Bartel G, Brehler R et al. Negativliste: Hautirritabilitäts- und Hautfunktionsdiagnostik zur Erfassung und Bewertung irritativer Hautschäden. ABD-Arbeitsgruppe “Erfassung und Bewertung irritativer Hautschäden”. Dermatol Beruf Umwelt 2006; 54: 108-11.
Robert Koch-Institut (RKI), Klein R, Idel H, Lehmann I. Diagnostische Relevanz des Lymphozytentransformationstestes in der Umweltmedizin. Mitteilung der Kommission „Methoden und Qualitätssicherung in der Umweltmedizin" am Robert Koch-Institut (RKI). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2002; 45: 745-9.
Lindemann M, Rietschel F, Zabel M, Grosse-Wilde H. Detection of chromium allergy by cellular in vitro methods. Clin Exp Allergy 2008; 38: 1468-75.
Becker D. In vitro delayed-type sensitivity testing. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1347-52.
Bergström MA, Ott H, Carlsson A et al. A skin-like cytochrome P450 cocktail activates prohaptens to contact allergenic metabolites. J Invest Dermatol 2007; 127: 1145-53.
Popple A, Williams J, Maxwell G et al. The lymphocyte transformation test in allergic contact dermatitis: New opportunities. J Immunotoxicol 2016; 13: 84-91.
Robert Koch-Institut (RKI), Klein R, Schwenk M. „Qualitätssicherung beim Lymphozytentransformationstest" - Addendum zum LTT-Papier der RKI-Kommission „Methoden und Qualitätssicherung in der Umweltmedizin". Mitteilung der Kommission „Methoden und Qualitätssicherung in der Umweltmedizin". Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008; 51: 1070-6.
Renz H, Biedermann T, Bufe A et al. In-vitro-Allergiediagnostik. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) unter Beteiligung des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA) und der Deutschen Dermatologische Gesellschaft (DDG). Allergo J 2010; 19: 110-28.
Pichler WJ. Lymphocyte transformation test. In: Vohr H-W: Encyclopedia of Immunotoxicology. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014: 1-5.
Brehler R, Merk H. In-vitro-Tests zum Nachweis von Kontaktallergien. Hautarzt 2005; 56: 1141-3.
Skazik C, Grannemann S, Wilbers L et al. Reactivity of in vitro activated human T lymphocytes to p-phenylenediamine and related substances. Contact Dermatitis 2008; 59: 203-11.
Skazik C, Merk HF, Baron JM. Diagnose der Kontaktallergie: Warum In-Vitro-Testsysteme? Hautarzt 2008; 59: 339-42.
Kneilling M, Caroli U, Grimmel C et al. Para-phenylenediamine-specific lymphocyte activation test: a sensitive in vitro assay to detect para-phenylenediamine sensitization in patients with severe allergic reactions. Exp Dermatol 2010; 19: 435-41.
Garzorz-Stark N, Eyerich K. Molekulare Diagnostik des Handekzems. Hautarzt 2019; 70: 760-5.
Fölster-Holst R. Differential diagnoses of diaper dermatitis. Pediatr Dermatol 2018; 35(Suppl 1): s10-s8.
Belloni Fortina A, Romano I, Peserico A, Eichenfield LF. Contact sensitization in very young children. J Am Acad Dermatol 2011; 65: 772-9.
Belloni Fortina A, Fontana E, Peserico A. Contact sensitization in children: A retrospective study of 2,614 children from a single center. Pediatr Dermatol 2016; 33: 399-404.
Deutsche Kontaktallergie-Gruppe (DKG). DKG Standardreihe für Kinder. 2021. Available from: https://dkg.ivdk.org/testreihen.html#a002 [Last accessed September 2, 2021].
Worm M, Aberer W, Agathos M et al. Patch testing in children - recommendations of the German Contact Dermatitis Research Group (DKG). J Dtsch Dermatol Ges 2007; 5: 107-9.
de Waard-van der Spek FB, Darsow U, Mortz CG et al. EAACI position paper for practical patch testing in allergic contact dermatitis in children. Pediatr Allergy Immunol 2015; 26: 598-606.
Schlaud M, Atzpodien K, Thierfelder W. Allergische Erkrankungen. Ergebnisse aus dem Kinder- und Jugendgesundheitssurvey (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 701-10.
Rzany B, Bechara FG, Feise K et al. Update of the S1 guidelines on the definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges 2018; 16: 945-52.
Werfel T, Heratizadeh A, Aberer W et al. Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 2021; 19: 151-68.
Werfel T, Aberer W, Ahrens F et al. Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis]. J Dtsch Dermatol Ges 2016; 14: e1-e75.
Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 1): 13-21.
Schuttelaar MLA, Oosterhaven JAF, Christoffers WA et al. Evidence-based management of hand eczema. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1399-416.
Seyfarth F, Schliemann S, Antonov D, Elsner P. Teaching interventions in contact dermatitis. Dermatitis 2011; 22: 8-15.
Andersen F, Andersen KE. Management of irritant contact dermatitis: continuously a problem for patients and dermatologists. G Ital Dermatol Venereol 2008; 143: 207-12.
Brar KK. A review of contact dermatitis. Ann Allergy Asthma Immunol 2021; 126: 32-9.
Ludriksone L, Antonov D, Schliemann S, Elsner P. Therapy of allergic and irritant contact dermatitis. In: Johansen JD, Mahler V, Lepoittevin JP, Frosch PJ: Contact Dermatitis. 6th Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2021: 1273-97.
Spiewak R. Immunotherapy of allergic contact dermatitis. Immunotherapy 2011; 3: 979-96.
Nielsen NH, Linneberg A, Menné T et al. Persistence of contact allergy among Danish adults: an 8-year follow-up study. Contact Dermatitis 2001; 45: 350-3.
Mastrolonardo M, Lopalco PL, Diaferio A. Topical immunotherapy with contact sensitizers: a model to study the natural history of delayed hypersensitivity. Contact Dermatitis 2002; 47: 210-4.
Dickel H, Kamphowe J, Geier J et al. Strip patch test vs. conventional patch test: investigation of dose-dependent test sensitivities in nickel- and chromium-sensitive subjects. J Eur Acad Dermatol Venereol 2009; 23: 1018-25.
Bauer A, Rönsch H, Elsner P et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev 2018; 4: CD004414.
Lachapelle J-M. Principles of prevention and protection in contact dermatitis (with special reference to occupational dermatology). In: Rycroft RJG, Menné T, Frosch PJ, Lepoittevin JP. Textbook of Contact Dermatitis. 3rd edition. Berlin Heidelberg New York Barcelona Hong Kong London Milan Paris Singapore Tokyo: Springer-Verlag, 2001: 979-93.
Sharma AD. Relationship between nickel allergy and diet. Indian J Dermatol Venereol Leprol 2007; 73: 307-12.
Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 2006; 17: 165-81.
Berthold E, Weisshaar E. Therapie des Handekzems. Hautarzt 2019; 70: 790-6.
Agner T, Jungersted JM. Emollients: effects, evidence, and side effects. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1451-9.
De Paépe K, Hachem JP, Vanpee E et al. Beneficial effects of a skin tolerance-tested moisturizing cream on the barrier function in experimentally-elicited irritant and allergic contact dermatitis. Contact Dermatitis 2001; 44: 337-43.
Ramsing DW, Agner T. Preventive and therapeutic effects of a moisturizer. An experimental study of human skin. Acta Derm Venereol (Stockh) 1997; 77: 335-7.
Lynde CW. Moisturizers: what they are and how they work. Skin Therapy Lett 2001; 6: 3-5.
Wohlrab J, Staubach P, Augustin M et al. S2k guidelines for the use of topical preparations on the skin. J Dtsch Dermatol Ges 2018; 16: 376-92.
European Parliament, The Council of the European Union. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast). Official Journal of the European Union 2009; L 342/59. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1613655218339&uri=CELEX:32009R1223.
Kraft M, Soost S, Worm M. Topical and systemic corticosteroids. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1433-44.
Luger T, Loske KD, Elsner P et al. Topische Dermatotherapie mit Glukokortikoiden - Therapeutischer Index. J Dtsch Dermatol Ges 2004; 2: 629-34.
Egeberg A, Schwarz P, Harsløf T et al. Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. JAMA Dermatol 2021; 157: 275-82.
Jackson RD. Topical corticosteroids and glucocorticoid-induced osteoporosis-cumulative dose and duration matter. JAMA Dermatol 2021; 157: 269-70.
Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999; 140: 882-6.
Isaksson M. Corticosteroids. Dermatol Ther 2004; 17: 314-20.
Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007; 215 (Suppl 1): 45-54.
Aschoff R, Schmitt J, Knuschke P et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1 % cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol 2011; 20: 832-6.
Mose KF, Andersen F, Røpke MA et al. Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone. Br J Clin Pharmacol 2018; 84: 1719-28.
Queille-Roussel C, Graeber M, Thurston M et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42: 349-50.
Engel K, Reuter J, Seiler C et al. Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. J Eur Acad Dermatol Venereol 2008; 22: 447-50.
Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-30.
Krejci-Manwaring J, McCarty MA, Camacho F et al. Topical tacrolimus 0.1 % improves symptoms of hand dermatitis in patients treated with a prednisone taper. J Drugs Dermatol 2008; 7: 643-6.
Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157-73.
Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003; 121: 77-80.
Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003; 49: 477-82.
Amrol D, Keitel D, Hagaman D, Murray J. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003; 91: 563-6.
Alomar A, Puig L, Gallardo CM, Valenzuela N. Topical tacrolimus 0.1 % ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1 % with greater suppression of late erythema. Contact Dermatitis 2003; 49: 185-8.
Schliemann S, Kelterer D, Bauer A et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis 2008; 58: 299-306.
Han JS, Won KH, Chang SE, Kim JE. Tacrolimus 0.1 % ointment in the treatment of allergic contact dermatitis: a new approach. Int J Dermatol 2014; 53: e470-e1.
Katsarou A, Makris M, Papagiannaki K et al. Tacrolimus 0.1 % vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol 2012; 22: 192-6.
Thelmo MC, Lang W, Brooke E et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat 2003; 14: 136-40.
Worm M, Bauer A, Elsner P et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol 2020; 182: 1103-10.
Schröder-Kraft C. Other topical therapies (dyes, tanning agents, tars, CO2). In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd Auflage. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1475-82.
Schmid MH, Korting HC. Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology 1996; 193: 1-5.
Skudlik C, Weisshaar E, Scheidt R et al. First results from the multicentre study rehabilitation of occupational skin diseases - optimization and quality assurance of inpatient management (ROQ). Contact Dermatitis 2012; 66: 140-7.
Skudlik C, Wulfhorst B, Gediga G et al. Tertiary individual prevention of occupational skin diseases: a decade’s experience with recalcitrant occupational dermatitis. Int Arch Occup Environ Health 2008; 81: 1059-64.
vanden Bogaard EH, Bergboer JGM, Vonk-Bergers M et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 2013; 123: 917-27.
Roelofzen JHJ, Aben KKH, Oldenhof UTH et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol 2010; 130: 953-61.
Roelofzen JH, Aben KK, van der Valk PG et al. Coal tar in dermatology. J Dermatolog Treat 2007; 18: 329-34.
vanSchooten FJ, Godschalk R. Coal tar therapy. Is it carcinogenic? Drug Saf 1996; 15: 374-7.
Pion IA, Koenig KL, Lim HW. Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg 1995; 21: 227-31.
Cholcha W, Leuschner J, Leuschner F. Untersuchungen zur Verträglichkeit von hellem sulfoniertem Schieferöl nach lokaler und systemischer Applikation. Arzneimittelforschung 1994; 44: 170-7.
Bickers DR, Kappas A. Human skin aryl hydrocarbon hydroxylase. Induction by coal tar. J Clin Invest 1978; 62: 1061-8.
Haarmann-Stemmann T, Esser C, Krutmann J. The Janus-faced role of aryl hydrocarbon receptor signaling in the skin: consequences for prevention and treatment of skin disorders. J Invest Dermatol 2015; 135: 2572-6.
Merk HF. Aryl-Hydrocarbon-Rezeptor als Zielstruktur für neue Medikamente bei Psoriasis und atopischer Dermatitis. Hautarzt 2019; 70: 942-7.
Tzaneva S, Kittler H, Thallinger C et al. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoimmunol Photomed 2009; 25: 101-5.
Stege H. Ultravioletttherapie des chronischen Handekzems. Hautarzt 2008; 59: 696-702.
Warshaw E, Lee G, Storrs FJ. Hand dermatitis: a review of clinical features, therapeutic options, and long-term outcomes. Am J Contact Dermat 2003; 14: 119-37.
Gritiyarangsan P, Sukhum A, Tresukosol P, Kullavanijaya P. Topical PUVA therapy for chronic hand eczema. J Dermatol 1998; 25: 299-301.
Sjövall P, Christensen OB. Treatment of chronic hand eczema with UV-B Handylux in the clinic and at home. Contact Dermatitis 1994; 31: 5-8.
Sjövall P, Christensen OB. Local and systemic effect of ultraviolet irradiation (UVB and UVA) on human allergic contact dermatitis. Acta Derm Venereol (Stockh) 1986; 66: 290-4.
Mørk NJ, Austad J. Short-wave ultraviolet light (UVB) treatment of allergic contact dermatitis of the hands. Acta Derm Venereol (Stockh) 1983; 63: 87-9.
Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23: 10-4.
Petering H, Breuer C, Herbst R et al. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004; 50: 68-72.
Schmidt T, Abeck D, Boeck K et al. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol (Stockh) 1998; 78: 318-9.
Bauer A, Kelterer D, Bartsch R et al. Prevention of hand dermatitis in bakers’ apprentices: different efficacy of skin protection measures and UVB hardening. Int Arch Occup Environ Health 2002; 75: 491-9.
Hölzle E. Iontophoresis. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1461-74.
Wollina U, Uhlemann C, Elstermann D et al. Therapie der Hyperhidrosis mittels Leitungswasseriontophorese. Positive Effekte auf Abheilungszeit und Rezidivfreiheit bei Hand-Fuss-Ekzemen. Hautarzt 1998; 49: 109-13.
Schempp CM, Czech W, Schöpf E, Simon JC. Leitungswasser-Iontophorese bei der Behandlung dyshidrotischer mit Hyperhidrosis assoziierter Palmoplantarekzeme. Akt Dermatol 1996; 22: 198-201.
Odia S, Vocks E, Rakoski J, Ring J. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol (Stockh) 1996; 76: 472-4.
Soost S, Worm M. Therapie berufsbedingter Hauterkrankungen. Hautarzt 2009; 60: 718-21.
Molin SC, Ruzicka T. Retinoids. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1417-31.
Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the Big Bang. Cell 2014; 157: 255-66.
Amann PM, Merk HF, Baron JM. Retinoide in der Dermatopharmakologie. Hautarzt 2014; 65: 98-105.
Ruzicka T, Lynde CW, Jemec GBE et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-17.
Ruzicka T, Larsen FG, Galewicz D et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004; 140: 1453-9.
Bissonnette R, Worm M, Gerlach B et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol 2010; 162: 420-6.
Song M, Lee H-J, Lee W-K et al. Acitretin as a therapeutic option for chronic hand eczema. Ann Dermatol 2017; 29: 385-7.
Politiek K, Christoffers WA, Coenraads PJ, Schuttelaar MLA. Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther 2016; 29: 364-71.
Tan J, Maari C, Nigen S et al. Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis. J Dermatolog Treat 2015; 26: 373-5.
Thestrup-Pedersen K, Andersen KE, Menné T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol (Stockh) 2001; 81: 353-5.
Granlund H, Erkko P, Reitamo S. Long-term follow-up of eczema patients treated with cyclosporine. Acta Derm Venereol (Stockh) 1998; 78: 40-3.
Granlund H, Erkko P, Reitamo S. Comparison of the influence of cyclosporine and topical betamethasone-17,21-dipropionate treatment on quality of life in chronic hand eczema. Acta Derm Venereol (Stockh) 1997; 77: 54-8.
Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol (Stockh) 1996; 76: 371-6.
Reitamo S, Granlund H. Cyclosporin A in the treatment of chronic dermatitis of the hands. Br J Dermatol 1994; 130: 75-8.
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21: 606-19.
Verma KK, Mahesh R, Srivastava P et al. Azathioprine versus betamethasone for the treatment of parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol 2008; 74: 453-7.
Agarwal US, Besarwal RK. Topical clobetasol propionate 0.05% cream alone and in combination with azathioprine in patients with chronic hand eczema: an observer blinded randomized comparative trial. Indian J Dermatol Venereol Leprol 2013; 79: 101-3.
da Mota R, Homey B. Treatment of chronic hand eczema: other immunomodulating therapies. In: John SM, Johansen JD, Rustemeyer T et al. Kanerva’s Occupational Dermatology. 3rd edition. Cham, Switzerland: Springer Nature Switzerland AG, 2020: 1445-50.
Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 2007; 20: 206-15.
Pickenäcker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 1998; 134: 378-9.
Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40: 612-4.
Jappe U, Beckert H, Bergmann KC et al. Biologics for atopic diseases: Indication, side effect management, and new developments. Allergol Select 2021; 5: 1-25.
Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol 2019; 28: 756-68.
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018; 78 (Suppl 1): S28-S36.
Bhatia J, Sarin A, Wollina U et al. Review of biologics in allergic contact dermatitis. Contact Dermatitis 2020; 83: 179-81.
Shirley M. Dupilumab: first global approval. Drugs 2017; 77: 1115-21.
Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat 2021; 32: 19-28.
Oosterhaven JAF, Voorberg AN, Romeijn GLE et al. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. J Dermatol 2019; 46: 680-5.
Crepy MN, Nosbaum A, Bensefa-Colas L. Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema. Contact Dermatitis 2019; 81: 145-7.
Machler BC, Sung CT, Darwin E, Jacob SE. Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol 2019; 80: 280-1.
Chipalkatti N, Lee N, Zancanaro P et al. Dupilumab as a treatment for allergic contact dermatitis. Dermatitis 2018; 29: 347-8.
Goldminz AM, Scheinman PL. A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther 2018; 31: e12701.
Joshi SR, Khan DA. Effective use of dupilumab in managing systemic allergic contact dermatitis. Dermatitis 2018; 29: 282-4.
Sattar H, Manzoor J, Mirza L et al. Iatrogenic Cushing’s syndrome in children presenting at Children’s Hospital Lahore using nappy rash ointments. J Pak Med Assoc 2015; 65: 463-6.
Blume-Peytavi U, Hauser M, Lünnemann L et al. Prevention of diaper dermatitis in infants - a literature review. Pediatr Dermatol 2014; 31: 413-29.
Foti C, Bonifazi E, Casulli C et al. Contact allergy to topical corticosteroids in children with atopic dermatitis. Contact Dermatitis 2005; 52: 162-3.
Korting HC, Schöllmann C, Cholcha W et al. Efficacy and tolerability of pale sulfonated shale oil cream 4 % in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. J Eur Acad Dermatol Venereol 2010; 24: 1176-82.
Slutsky JB, Clark RAF, Remedios AA, Klein PA. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 2010; 9: 1258-64.
Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-82.
American Academy of Pediatrics Committee on Drugs. Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics 1990; 86: 797-8.
Brans R, Skudlik C. Prävention des Handekzems. Hautarzt 2019; 70: 797-803.
Fartasch M, Diepgen TL, Drexler H et al. S1-Leitlinie „Berufliche Hautmittel: Hautschutz, Hautpflege und Hautreinigung“ (ICD 10: L23, L24) - Kurzversion. J Dtsch Dermatol Ges 2015; 13: 594-607.
Lachapelle JM. Efficacy of protective creams and/or gels. Curr Probl Dermatol 1996; 25: 182-92.
Lodén M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 1997; 36: 256-60.
Mathias CG. Prevention of occupational contact dermatitis. J Am Acad Dermatol 1990; 23: 742-8.
Wigger-Alberti W, Elsner P. Preventive measures in contact dermatitis. Clin Dermatol 1997; 15: 661-5.
Hannuksela M. Moisturizers in the prevention of contact dermatitis. Curr Probl Dermatol 1996; 25: 214-20.
Zhai H, Maibach HI. Moisturizers in preventing irritant contact dermatitis: an overview. Contact Dermatitis 1998; 38: 241-4.
Williams C, Wilkinson SM, McShane P et al. A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use. Br J Dermatol 2010; 162: 1088-92.
Bruusgaard-Mouritsen MA, Johansen JD, Zachariae C et al. Natural ingredients in cosmetic products - A suggestion for a screening series for skin allergy. Contact Dermatitis 2020; 83: 251-70.
Dinkloh A, Worm M, Geier J et al. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. J Eur Acad Dermatol Venereol 2015; 29: 1071-81.
Nguyen HL, Yiannias JA. Contact dermatitis to medications and skin products. Clin Rev Allergy Immunol 2019; 56: 41-59.
Uter W, Geier J, Lessmann H, Schnuch A. Inhaltsstoffe von Hautschutz- und -pflegemitteln aus allergologischer Sicht. Analyse von IVDK-Daten und Literaturübersicht. Dermatol Beruf Umwelt 2005; 53: 172-82.
Wetter DA, Yiannias JA, Prakash AV et al. Results of patch testing to personal care product allergens in a standard series and a supplemental cosmetic series: an analysis of 945 patients from the Mayo Clinic Contact Dermatitis Group, 2000-2007. J Am Acad Dermatol 2010; 63: 789-98.
Agner T, Held E. Skin protection programmes. Contact Dermatitis 2002; 47: 253-6.
Kütting B, Drexler H. Der dreistufige Hautschutzplan. Ein wirksames Instrument der Primärprävention oder eher geeignet für die Sekundärprävention? Dtsch Med Wochenschr 2008; 133: 201-5
Frosch PJ, Kurte A. Efficacy of skin barrier creams (IV). The repetitive irritation test (RIT) with a set of 4 standard irritants. Contact Dermatitis 1994; 31: 161-8.
Kresken J, Klotz A. Occupational skin-protection products - a review. Int Arch Occup Environ Health 2003; 76: 355-8.
Wigger-Alberti W, Caduff L, Burg G, Elsner P. Experimentally induced chronic irritant contact dermatitis to evaluate the efficacy of protective creams in vivo. J Am Acad Dermatol 1999; 40: 590-6.
Zhai H, Maibach HI. Effect of barrier creams: human skin in vivo. Contact Dermatitis 1996; 35: 92-6.
Schliemann S, Petri M, Elsner P. Preventing irritant contact dermatitis with protective creams: influence of the application dose. Contact Dermatitis 2014; 70: 19-26.
Schliemann S, Kleesz P, Elsner P. Protective creams fail to prevent solvent-induced cumulative skin irritation - results of a randomized double-blind study. Contact Dermatitis 2013; 69: 363-71.
Lejding T, Engfeldt M, Bruze M et al. Can reducing cosmetic substances help prevent chromate contact allergy? Contact Dermatitis 2020; 82: 39-44.
Lejding T, Engfeldt M, Bruze M et al. Skin application of glutathione and iron sulfate can inhibit elicitation of allergic contact dermatitis from hexavalent chromium. Contact Dermatitis 2020; 82: 45-53.
Marks JG, Jr, Fowler JF, Jr, Sheretz EF, Rietschel RL. Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite. J Am Acad Dermatol 1995; 33: 212-6.
Vidmar DA, Iwane MK. Assessment of the ability of the topical skin protectant (TSP) to protect against contact dermatitis to urushiol (Rhus) antigen. Am J Contact Dermat 1999; 10: 190-7.
Wöhrl S, Kriechbaumer N, Hemmer W et al. A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals. Contact Dermatitis 2001; 44: 224-8.
Brehler R, Maurer O, Grabbe S, Schwarz T. Topically applied pentoxifylline has no effect on allergic patch responses. J Am Acad Dermatol 1998; 39: 1017-21.
Wilke A, Skudlik C, Sonsmann FK. Individualprävention beruflicher Kontaktekzeme: Schutzhandschuhe und Hautschutzempfehlungen im berufsgenossenschaftlichen Heilverfahren. Hautarzt 2018; 69: 449-61.
Allmers H, Schmengler J, John SM. Decreasing incidence of occupational contact urticaria caused by natural rubber latex allergy in German health care workers. J Allergy Clin Immunol 2004; 114: 347-51.
Geier J, Lessmann H, Mahler V et al. Occupational contact allergy caused by rubber gloves - nothing has changed. Contact Dermatitis 2012; 67: 149-56.
Hamnerius N, Svedman C, Bergendorff O et al. Wet work exposure and hand eczema among healthcare workers: a cross-sectional study. Br J Dermatol 2018; 178: 452-61.
Ramsing DW, Agner T. Effect of glove occlusion on human skin (I). Short-term experimental exposure. Contact Dermatitis 1996; 34: 1-5.
Ramsing DW, Agner T. Effect of glove occlusion on human skin (II). Long-term experimental exposure. Contact Dermatitis 1996; 34: 258-62.
Tiedemann D, Clausen ML, John SM et al. Effect of glove occlusion on the skin barrier. Contact Dermatitis 2016; 74: 2-10.
Wigger-Alberti W, Elsner P. Do barrier creams and gloves prevent or provoke contact dermatitis? Am J Contact Dermat 1998; 9: 100-6.
Pedersen LK, Held E, Johansen JD, Agner T. Less skin irritation from alcohol-based disinfectant than from detergent used for hand disinfection. Br J Dermatol 2005; 153: 1142-6.
Slotosch CM, Kampf G, Löffler H. Effects of disinfectants and detergents on skin irritation. Contact Dermatitis 2007; 57: 235-41.
Rodriguez-Homs LG, Atwater AR. Allergens in medical hand skin cleansers. Dermatitis 2019; 30: 336-41.
Krohn S, Drechsel-Schlund C, Römer W et al. Rechtsänderungen bei Berufskrankheiten - Auswirkungen auf die dermatologische Praxis. Dermatol Beruf Umwelt 2020; 68: 145-8.